Researchers at UCLA Jonsson Comprehensive Cancer Center led a large international study providing what is believed to be the first evidence (albeit indirect) that a recently approved imaging technique ...
The University of California's two nationally ranked medical centers, UCSF and UCLA, and their nuclear medicine teams have obtained approval from the U.S. Food and Drug Administration to offer a new ...
SAN FRANCISCO and LOS ANGELES - The University of California's two nationally ranked medical centers, UCSF and UCLA, and their nuclear medicine teams have obtained approval from the U.S. Food and Drug ...
The University of California San Francisco and UC Los Angeles received FDA approval Dec. 1 for a new prostate cancer imaging technique that uses a positron emission tomography-sensitive tracer drug to ...
Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.
University of California prostate cancer experts will share clinical insights at the first annual PSMA Conference, “PSMA PET and RLT: Present and Future.” The conference will take place online and ...
A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...
A new study led by researchers at the UCLA Jonsson Comprehensive Cancer Center helps identify which patients with prostate cancer will benefit most from the use of prostate-specific membrane antigen ...
A revolutionary new diagnostic method for prostate cancer can detect prostate cancer cells that have spread to lymph nodes both inside and outside the pelvis, according to the UC San Francisco and ...
Jeremie Calais, MD, comments on how PSMA PET scans have changed the treatment landscape for patients with mCRPC and describes the process for obtaining a PSMA PET scan, including what patients should ...
The use of a nomogram derived from prostate-specific membrane antigen (PSMA) PET/CT findings successfully predicted long-term outcomes in patients with high-risk and very high-risk prostate cancer, ...
The University of California San Francisco and UC Los Angeles received FDA approval Dec. 1 for a new prostate cancer imaging technique that uses a positron emission tomography-sensitive tracer drug to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback